Last reviewed · How we verify

NCT03059550: REHABDIAB

Screening for Glucose Metabolism Disorders in Cardiac Rehabilitation

Status unknown Last updated 19 July 2018
What this trial tests

trial in Diabetes in 350 participants. Status unknown.

Timeline
1 March 2013
Primary endpoint
31 May 2015
31 December 2020

Quick facts

Lead sponsorCentre Hospitalier Universitaire Dijon
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment350
Start date1 March 2013
Primary completion31 May 2015
Estimated completion31 December 2020
Sites1 location across France

Conditions studied

Sponsor

Centre Hospitalier Universitaire Dijon

Who can join

18 and older, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Because prevalence of glucose metabolism disorders is high in patients with coronary disease, the Oral Glucose Tolerance Test (OGTT) is recommended in all patients without diabetes after an acute coronary syndrome (ACS). However, there are some concerns about its performance in clinical practice. The aim of our study was to evaluate, after an acute coronary syndrome (ACS), the feasibility and efficacy of the OGTT in a cardiac rehabilitation (CR) center in comparison with its real application in the whole French population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire Dijon trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03059550.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing